News MoonLake Immunotherapeutics

Equities

MLTX

KY61559X1045

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
39.75 ^USD	-2.72%		-2.86%	-34.18%

07/05	MoonLake Immunotherapeutics Q1 Net Loss Widens	MT
07/05	MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa	16/05	GL
MoonLake Immunotherapeutics Q1 Net Loss Widens	07/05	MT
MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update	07/05	AQ
MoonLake Immunotherapeutics, Komodo Health Team Up to Improve Inflammatory Skin, Joint Diseases Treatment	10/04	MT
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions	10/04	BU
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions	10/04	AQ
Goldman Sachs Initiates MoonLake Immunotherapeutics at Neutral With $62 Price Target	02/04	MT
Health Care Dips Amid Regulatory Doubts -- Health Care Roundup	12/03	DJ
HC Wainwright Adjusts Price Target on MoonLake Immunotherapeutics to $100 From $75, Maintains Buy Rating	11/03	MT
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day	10/03	AQ
MoonLake Immunotherapeutics Announces Significant Improvements with Nanobody Sonelokimab over 24 Weeks in Active Psoriatic Arthritis	10/03	CI
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day	10/03	GL
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024	04/03	GL
Moonlake Immunotherapeutics to Present MIRA Trial Data of Nanobody Sonelokimab in Hidradenitis Suppurativa as A Late Breaker At the AAD Annual Meeting 2024	04/03	CI
Moonlake Immunotherapeutics Insider Sold Shares Worth $6,803,044, According to a Recent SEC Filing	01/03	MT
Moonlake Immunotherapeutics Insider Sold Shares Worth $6,540,710, According to a Recent SEC Filing	01/03	MT
MoonLake Immunotherapeutics Shares Decline After Posting Q4 Loss	29/02	MT
MoonLake Immunotherapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
MoonLake Immunotherapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News MoonLake Immunotherapeutics

Equities

MLTX

KY61559X1045

Summary

Filters